PAF increases vascular permeability in selected tissues: Effect of BN-52021 and L-655,240

This publication has 32 references indexed in Scilit:

• Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropanoic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist
  European Journal of Pharmacology, 1987
• Pharmacological profiles of a potential LTB4-antagonist, SM-9064
  Biochemical and Biophysical Research Communications, 1986
• Acute microvascular effects of PAF-acether, as studied by intravital microscopy
  European Journal of Pharmacology, 1983
• Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.
  Journal of Clinical Investigation, 1983
• Activities of enzymes that metabolize platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in neutrophils and eosinophils from humans and the effect of a calcium ionophore
  Biochemical and Biophysical Research Communications, 1982
• BACKGROUND AND PRESENT STATUS OF RESEARCH ON PLATELET‐ACTIVATING FACTOR (PAF‐ACETHER)
  Annals of the New York Academy of Sciences, 1981
• Human platelet stimulation by acetyl glyceryl ether phosphorylcholine.
  Journal of Clinical Investigation, 1981
• Release of platelet‐activating factor (PAF‐acether) from alveolar macrophages by the calcium ionophore A 23187 and phagocytosis
  European Journal of Clinical Investigation, 1980
• Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives
  European Journal of Pharmacology, 1980
• Platelet‐activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes
  European Journal of Immunology, 1979